Results 191 to 200 of about 63,203 (259)

Multicenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP-Ribose) Polymerase Inhibitor Veliparib. [PDF]

J Am Heart Assoc
Koehler RC, Bedirian K, Chen MH, Shi Y, Cao S, Avery BD, Karuppagounder SS, Akhter K, Bibic A, Dawson VL, Dawson TM, Diniz MA, Lamb J, Nagarkatti KA, Chauhan A, Aronowski J, McCullough LD, de Morais AL, Jin X, Ayata C, Kumskova M, Patel RB, Chauhan AK, Leira EC, Kamat PK, Khan MB, Dhandapani KM, Hess DC, Boisserand LSB, Sanganahalli BG, Sansing LH, Lyden PD, SPAN investigators [Link].   +32 more
europepmc   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, Volume 50, Issue 8, Page 2106-2115, August 2026.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

FMRP‐Mediated Proteasome Regulation: A Novel Mechanism in ALS Pathology

The FASEB Journal, Volume 40, Issue 13, 15 July 2026.
Schematic model of TDP‐43/TNKS‐mediated proteasome regulation in WT, FMRP‐depleted, and TDP‐43A315T‐Tg ALS neurons. In WT neurons, cytoplasmic TDP‐43 partially sequesters TNKS, maintaining balanced PI31 ribosylation and proteasome activity. FMRP depletion promotes nuclear translocation of TDP‐43, enhances TNKS/PI31 interaction, and increases axonal ...
Pritha Majumder, Asmar Ahsan, Pitchapa Bubphachat, Khadiza Akter, Jeffrey K. Huang, Chi‐Chen Sarah Huang   +5 more
wiley   +1 more source

The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments - parallels with other neurodegenerative disorders. [PDF]

Front Pharmacol
Ordaz DA, Gupta K, Bota DA.
europepmc   +1 more source

Synthesis of Novel Substituted <i>N</i>‑Heterocycles and Their Use of Selective Poly(ADP-ribose) Polymerase 1 (PARP1) Inhibitors. [PDF]

ACS Med Chem Lett
Zhou X, Liang SH.
europepmc   +1 more source

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer. [PDF]

Oncologist
Rimel BJ, Pujade-Lauraine E, Moore K, Pfisterer J, Han S, Cibula D, Reyners A, Redondo A, Papadimitriou C, Eitan R, Pignata S, Glasspool R, Mirza MR, Bodnar L, Duska L, Provencher D, Phaëton R, Bains M, Coskuncay E, Hardy-Bessard AC.   +19 more
europepmc   +1 more source

Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study. [PDF]

Oncol Res
Piątek S, Dańska-Bidzińska A, Derlatka P, Szymanowski B, Duchnowska R, Zielińska A, Sawicka N, Gorzeń A, Michalski W, Bidziński M.   +9 more
europepmc   +1 more source

Poly(ADP-ribose) polymerase-1 (PARP-1) gene polymorphisms in schizophrenia: A case-control study in the Turkish population. [PDF]

Medicine (Baltimore)
Şenormanci Ö, Turan Ç, Metin S, Karakaş Çelik S, Yilmaz B, Şenormanci G, Ünal S.   +6 more
europepmc   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

British Journal of Haematology, Volume 209, Issue 2, Page 786-792, August 2026.
Mawar Karsa, Ayu Karsa, Dayna Spurling, Lin Xiao, Emma Ronca, Angelika Bongers, Weiman Gao, Andrew J. Gifford, Ali El‐Ayoubi, Laurence C. Cheung, Rishi S. Kotecha, Richard B. Lock, Charis E. Teh, Guillaume Lessene, Murray D. Norris, Andrew Wei, Michelle Haber, Michelle J. Henderson, Donia M. Moujalled, Klaartje Somers   +19 more
wiley   +1 more source

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol
Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM.   +6 more
europepmc   +1 more source